向美国中毒中心报告的2000-2021年涉及抗精神病药或镇静催眠药的疑似自杀与自杀未遂
该研究回顾性分析2000-2021年美国国家中毒数据系统数据,共972,975例涉及抗精神病药或镇静催眠药的疑似自杀/自杀未遂,年均44,226例。每10万人口报告暴露率从2000年27.2显著升至2008年49.1(P<0.0001),2016年49.6趋于平台(P=0.1497),2021年显著降至38.7(P<0.0001);13-19岁人群从28.4升至79.6(P<0.0001),增幅最大。48.8%主要物质为苯二氮䓬类,36.7%为抗精神病药;36.1%出现严重医学结局,包括1,330例死亡。49岁以上者严重结局(RR=1.25)、死亡(RR=3.06)及入住重症/非重症病房(RR=1.24)风险均高于年轻者。
要点
- 2000-2021年共972,975例涉及抗精神病药或镇静催眠药的疑似自杀/自杀未遂,年均44,226例。
- 13-19岁人群报告率从2000年28.4/10万升至2021年79.6/10万(P<0.0001),增幅最大。
- 48.8%主要物质为苯二氮䓬类,36.7%为抗精神病药,14.6%为其他镇静/催眠/抗焦虑或抗精神病药。
- 36.1%出现严重医学结局,包括1,330例死亡;43.3%入住重症或非重症病房,27.9%直接入精神科机构。
- 49岁以上者严重医学结局RR=1.25(95%CI 1.24-1.26)、死亡RR=3.06(95%CI 2.74-3.41)、入住重症或非重症病房RR=1.24(95%CI 1.23-1.24),均高于年轻者。
适用人群与场景
- 2000-2021年向美国中毒中心报告的涉及抗精神病药或镇静催眠药作为主要物质的疑似自杀或自杀未遂病例,共972,975例。
- 85.6%的病例年龄>19岁,女性占63.5%,51.8%为单一物质暴露。
研究设计与关键结果
- 研究类型:基于美国国家中毒数据系统2000-2021年数据的回顾性分析。
- 每10万美国人口报告暴露率从2000年27.2显著升至2008年49.1(P<0.0001),2016年49.6趋于平台(P=0.1497),2021年显著降至38.7(P<0.0001)。
- 13-19岁人群报告率从2000年28.4升至2021年79.6(P<0.0001),增幅最大。
- 主要物质:苯二氮䓬类48.8%,抗精神病药36.7%,其他镇静/催眠/抗焦虑或抗精神病药14.6%。
- 处置去向:43.3%入住重症或非重症病房,27.9%直接入精神科机构;36.1%出现严重医学结局,包括1,330例死亡。
- 49岁以上者较年轻者更易出现严重医学结局(RR=1.25,95%CI 1.24-1.26)、死亡(RR=3.06,95%CI 2.74-3.41)或入住重症/非重症病房(RR=1.24,95%CI 1.23-1.24)。
证据类型、等级与局限
- 证据类型:基于美国国家中毒数据系统的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于本研究识别的特征和趋势,需要加强预防措施以帮助预防这些疑似自杀和自杀未遂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the patterns and trends of suspected suicides and suicide attempts involving antipsychotic or sedative-hypnotic medications reported to United States poison centers.
METHODS: Data from the National Poison Data System for 2000 through 2021 were retrospectively analyzed.
RESULTS: There were 972,975 suspected suicides and suicide attempts with antipsychotics or sedative-hypnotics ranked as the primary substance reported to poison centers from 2000-2021, averaging 44,226 cases annually. Most (85.6%) cases occurred among individuals >19 years old, females accounted for 63.5% of cases, and 51.8% were single-substance exposures. The rate of reported exposures per 100,000 United States population increased significantly from 27.2 in 2000 to 49.1 in 2008 (P < 0.0001), then plateaued to 49.6 in 2016 (P = 0.1497), followed by a significant decrease to 38.7 in 2021 (P < 0.0001). Individuals 13-19 years old demonstrated the greatest increase in rate from 28.4 in 2000 to 79.6 in 2021 (P < 0.0001). Approximately half (48.8%) of primary substance exposures were benzodiazepines, followed by antipsychotic medications (36.7%) and other types of sedative/hypnotic/anti-anxiety or antipsychotic medications (14.6%). Most primary substance exposures were admitted to a critical care or non-critical care unit (43.3%) or directly to a psychiatric facility (27.9%), and 36.1% were associated with in a serious medical outcome, including 1,330 deaths. Individuals >49 years old were more likely to experience a serious medical outcome (relative risk = 1.25, 95% CI: 1.24-1.26), including death (relative risk = 3.06, 95% CI: 2.74-3.41), or be admitted to a critical care or non-critical care unit (relative risk = 1.24, 95% CI: 1.23-1.24) than younger individuals.
CONCLUSIONS: Suspected suicides and suicide attempts involving antipsychotic or sedative-hypnotic medications increased during the 22-year study period, especially among individuals 13-19 years old, and these cases often had severe clinical consequences. Based on the characteristics and trends identified in this study, increased prevention efforts are warranted to help prevent these suspected suicides and suicide attempts.
参考来源
- Ybanez L, Spiller HA, Badeti J, et al. Suspected suicides and suicide attempts involving antipsychotic or sedative-hypnotic medications reported to America's Poison Centers, 2000-2021. Clin Toxicol (Phila). 2023. PMID: 37010386. doi:10.1080/15563650.2023.2185493
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。